SOURCE: diaDexus, Inc.

Diadexus, Inc.

August 06, 2015 09:15 ET

Diadexus, Inc. to Report Second Quarter 2015 Financial Results on August 13, 2015

Conference Call and Webcast Scheduled for 4:30 p.m. ET (1:30 p.m. PT)

SOUTH SAN FRANCISCO, CA--(Marketwired - Aug 6, 2015) - Diadexus, Inc. (OTCQB: DDXS), a diagnostics company developing and commercializing products that aid in the prediction of cardiac disease risk, today announced that it will report second quarter 2015 financial results on Thursday, August 13, 2015 after market close, and will host a conference call to discuss financial results and provide a business update at 4:30 p.m. ET (1:30 p.m. PT).

To access the webcast, visit the Company's website at http://investors.diadexus.com/events.cfm. To access the conference call, dial (855) 666-6874 for domestic callers and (262) 912-6259 for international callers. The reservation number for both is 93519113. A replay of the webcast will be available shortly following the live webcast for a period of four weeks.

About Diadexus, Inc.

Diadexus, based in South San Francisco, California, is a diagnostics company developing and commercializing products that aid in the prediction of cardiac disease risk, providing healthcare providers with actionable information for managing patients. The Company pioneered the testing of Lp-PLA2 (lipoprotein-associated phospholipase A2), a marker of vascular-specific inflammation that provides new information, over and above traditional risk factors measured in a lipid panel, and has over a decade of peer-reviewed literature validating its utility. Diadexus' products, The PLAC® Test ELISA Kit, first cleared by the FDA in 2003, and The PLAC® Test for Lp-PLA2 Activity, cleared in December 2014, are the only two FDA-cleared tests to measure Lp-PLA2.

The Company also has a pipeline of biomarkers for heart failure, proADM, proET-1 and proANP, with each providing distinct, additive information for healthcare providers over currently available markers. Diadexus also provides services to pharmaceutical partners to address the need to incorporate biomarkers in clinical development. For more information, please visit the Company's website at www.diadexus.com.

Contact Information

  • CONTACT:

    Leone Patterson
    650-246-6432
    Chief Financial Officer
    Email Contact